Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a
Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a
复制标题
DOI：
10.1517/17425247.2014.943181
复制
发表时间：
2014-11
影响因子：
6.6
通讯作者：
V. Limmroth;K. Gerbershagen
中科院分区：
文献类型：
--
作者：
V. Limmroth;K. Gerbershagen
简介：IFNβ产品和醋酸格拉替雷是多发性硬化症（MS）长期疾病改善治疗的既定一线治疗选择。这些自我注射药物每周使用一次至每天一次。注射相关问题是患者引用的不依从的常见原因。自动注射器已被证明支持长期坚持注射药物。MS患者自我注射的能力与错过注射和停药的风险降低有关，对患者的独立性有有益的影响。涵盖的领域：最近推出的易于使用的预充式每周一次注射笔是一种安全有效的肌内（IM）IFNβ-1a应用装置，并提供了一种方便的自我注射方法。我们审查了关于该器械特征的可用已发表证据。每周一次注射笔有助于自我注射，在一项针对MS患者的前瞻性开放标签、多中心IIIb期试验中，患者首选使用预充式注射器IM IFNβ-1a。专家意见：该器械操作简单、安全、屏蔽短针、一次性使用设计以及几乎无痛注射，可能有助于使用IM IFNβ-1a的患者的依从性、生活质量和独立性。
Introduction: IFNβ products and glatiramer acetate are established treatment first-line options in long-term disease-modifying therapy of multiple sclerosis (MS). These self-injectable medications are used once weekly to once daily. Injection-related issues are common patient-cited reasons for nonadherence. Autoinjectors have been shown to support long-term adherence to injectable medications. The ability to self-inject in MS patients has been associated with a reduced risk of missed injections and drug discontinuation, and a beneficial effect on patient independence. Areas covered: The recently introduced easy-to-use prefilled once-weekly pen is a safe and effective device for intramuscular (IM) IFNβ-1a application and provides a convenient method for self-injection. We reviewed the available published evidence on the characteristics of this device. The once-weekly pen facilitates self-injection and was preferred over prefilled syringes by patients in a prospective open-label, multicenter Phase IIIb trial in MS patients who had been using IM IFNβ-1a in prefilled syringes. Expert opinion: The simple and safe handling, shielded short needle, single-use disposable design and virtually painless injection by the device may contribute to adherence, quality of life and independence in patients using IM IFNβ-1a.